(919) 237-4897 info@t3dtherapeutics.com

T3D Therapeutics, Inc. has achieved a significant clinical trial milestone in its Phase 2a feasibility study in mild to moderate Alzheimer’s disease patients with T3D-959, an investigational new drug candidate that has the potential to be transformative by slowing, stopping or reversing Alzheimer’s disease.

Read More